Bringing the Oncology Community Together

Julian Adams on the IPI-145 Mechanism of Action

Julian Adams, PhD
Published Online: Wednesday, June 26, 2013
Julian Adams, PhD, the president of research and development at Infinity Pharmaceuticals, describes the mechanism of action for the experimental PI3 kinase delta/gamma inhibitor IPI-145 in hematologic malignancies.

PI3 kinase, specifically the delta and gamma isoforms, are expressed ubiquitously on cells associated with the immune system, specifically B cells, T cells, and cells of myeloid origin. In general, Adams notes, PI3 kinase is the master regulator of cellular activation, proliferation, survival, and intracellular trafficking. It is utilized by hematologic malignancies for trafficking into the lymph cells, where the cancer survives.

Inhibiting PI3 kinase delta/gamma forces the cancer cells out of the lymph node microenvironment, Adams suggests. Once blocked from the lymph cells, the cancer is restricted to the peripheral blood, where it dies.

Related Articles
New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
Epizyme Maintains Independence, Advances HMT-Inhibitor Platform
Epizyme, a Cambridge, Massachusetts-based biotech, opted for independence, with a successful IPO in 2013.
MSK's CAR Trials Halted Temporarily Amid Safety Review
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.